Anti TAA x CD3 x PD-L1 trispecific antibody - RemeGen Biosciences
Alternative Names: TICTELatest Information Update: 12 Jul 2024
At a glance
- Originator RemeGen Biosciences
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours